Advances in cancer research. Volume 95

Published
  • New York : Academic Press 2006
Physical description
1 online resource (370 p.)
ISBN
  • 1-280-63636-X
  • 9786610636365
  • 0-08-046448-3
Notes
  • Description based upon print version of record.
  • Includes bibliographical references and index.
  • Source of acquisition: QU01110632.
  • English
  • Print version record.
Contents
  • Cover Page; Title Page; Copyright Page; Contnets; Contributors to Volume 95; Chapter 1: NY-ESO-1: Review of an Immunogenic Tumor Antigen; I. Identity Card: Background Information for NY-ESO-1; II. Package Insert: Therapeutic Potential of NY-ESO-1; III. Concluding Remarks; Acknowledgments; References; Chapter 2: Order, Disorder, Death: Lessons from a Superorganism; I. Order in Living Organisms; II. Superorganisms; III. Honeybee Society; IV. Regulation of Differentiation, Growth, and Homeostasis; V. Regulation of Death; VI. Order, Disorder, and Disease; VII. Conclusions; Acknowledgments
  • ReferencesChapter 3: Control of Differentiation in Progression of Epithelial Tumors; I. Introduction; II. Normal Epitheliocyte; III. Microenvironmental Control of Transformed Cells; IV. Concluding Remarks and Further Perspective; Acknowledgments; References; Chapter 4: Cancer Vaccines: Preclinical Studies and Novel Strategies; I. Introduction; II. Types of Targets for Vaccine Therapy; III. Vaccine Strategies; IV. Biological Adjuvants; V. Multimodal Therapies; VI. Next-Generation Vaccine Design and Delivery; VII. Challenges in Cancer Vaccine Design; VIII. Conclusions; Acknowledgments
  • ReferencesChapter 5: Clinical Results of Vaccine Therapy for Cancer: Learning from History for Improving the Future; I. Introduction; II. Vaccine Trials in B-Cell Malignancies; III. B-Cell Chronic Lymphocytic Leukemia; IV. Multiple Myeloma; V. Vaccine Trials in Solid Tumors; VI. Incorporation of Vaccine Treatment into Chemotherapy Regimens; VII. Relevance of Regulatory T-Cells for Vaccine Therapy of Cancer; VIII. Immunological Adjuvants for Cancer Vaccines; IX. Conclusions; References
  • Chapter 6: Immunodominance and Immunodomination: Critical Factors in Developing Effective CD8+ T-Cell-Based Cancer VaccinesI. Introduction; II. The Phenomenon: Immunodominance; III. Theoretical Contributions of Antigen Processing and Presentation to Immunodominance; IV. Immunodomination and its Possible Mechanisms; V. Immunodominance is Susceptible to Viral Escape; VI. Immunodominance in Antitumor Responses and Tumor Escape; VII. Immunodominance and Cancer Vaccines; VIII. Conclusions; Acknowledgments; References; Chapter 7: NK Cell Receptors as Tools in Cancer Immunotherapy; I. Introduction
  • II. NK Cell Recognition of Tumor CellsIII. NK Cell Receptors; IV. Blocking Inhibitory Receptors to Activate Immunity; V. Use of Activating NK Receptors or Ligands in Cancer Immunotherapy; VI. Chimeric NK Cell Receptors as Cancer Immunotherapy; VII. Conclusions; Acknowledgments; References; Chapter 8: Innate Immune Recognition and Suppression of Tumors; I. Tumor Immune Surveillance: An Introduction; II. The Immune System is an Extrinsic Tumor Suppressor; III. Synposis of an Effective Immune Response; IV. Innate and Adaptive Immune Cells that Control Tumors
  • V. Immune Molecules that Recognize and Control Cancer
Related item
Genre
  • Bibliography
  • Electronic books.
  • Illustrated
  • text
Language
  • English

Summary

  • The Advances in Cancer Research series provides invaluable information on the exciting and fast-moving field of cancer research. This volume presents outstanding and original reviews on a variety of topics including NY-ESO-1: review of an immunogenic tumor antigen; Order, disorder, death: lessons from a superorganism; Control of differentiation in progression of epithelial tumors; Cancer vaccines: preclinical studies and novel strategies; Clinical results of vaccine therapy for cancer: learning from history for improving the future; Immunodominance and immunodomination: critical factors

Summary holdings does not include live availability details. Select a library name for the full Holdings display.

Export: